| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/10/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 10/28/2022 | 79.64% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 08/16/2022 | 19.76% | SVB Leerink | $9 → $4 | Maintains | Outperform |
| 07/11/2022 | 169.46% | SVB Leerink | $13 → $9 | Maintains | Outperform |
| 04/26/2022 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 04/26/2022 | 289.22% | SVB Leerink | $33 → $13 | Maintains | Outperform |
| 09/07/2021 | 858.08% | Guggenheim | → $32 | Initiates Coverage On | → Buy |
| 09/07/2021 | 947.9% | Stifel | → $35 | Initiates Coverage On | → Buy |
| 09/07/2021 | 888.02% | SVB Leerink | → $33 | Initiates Coverage On | → Outperform |
What is the target price for Eliem Therapeutics (ELYM)?
The latest price target for Eliem Therapeutics (NASDAQ: ELYM) was reported by HC Wainwright & Co. on February 10, 2023. The analyst firm set a price target for $0.00 expecting ELYM to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Eliem Therapeutics (ELYM)?
The latest analyst rating for Eliem Therapeutics (NASDAQ: ELYM) was provided by HC Wainwright & Co., and Eliem Therapeutics downgraded their neutral rating.
When is the next analyst rating going to be posted or updated for Eliem Therapeutics (ELYM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eliem Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eliem Therapeutics was filed on February 10, 2023 so you should expect the next rating to be made available sometime around February 10, 2024.
Is the Analyst Rating Eliem Therapeutics (ELYM) correct?
While ratings are subjective and will change, the latest Eliem Therapeutics (ELYM) rating was a downgraded with a price target of $0.00 to $0.00. The current price Eliem Therapeutics (ELYM) is trading at is $3.34, which is out of the analyst's predicted range.